Sanofi SA
$
43.37
0.72 (1.69%)
On watch
| Volume: | 747,124 | Avg Vol (1m): | 1,324,869 |
| Market Cap $: | 107.28 Bil | Enterprise Value $: | 128.74 Bil |
| P/E (TTM): | 22.54 | P/B: | 1.67 |
| Earnings Power Value | 22.31 |
| Net Current Asset Value | -12.42 |
| Tangible Book | -3.23 |
| Projected FCF | 44.38 |
| Median P/S Value | 41.94 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 6/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 0.29 |
Cash-To-Debt ranked
higher than
99.07%
of
859
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
SNY:
0.29
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.14, Med: 0.56, Max: 10.62
Current: 0.29
|
| Equity-to-Asset | 0.53 |
Equity-to-Asset ranked
lower than
68.53%
of
788
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
SNY:
0.53
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: 0.48, Med: 0.58, Max: 0.65
Current: 0.53
|
| Debt-to-Equity | 0.42 |
Debt-to-Equity ranked
lower than
100.00%
of
596
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
SNY:
0.42
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: 0.06, Med: 0.21, Max: 0.42
Current: 0.42
|
| Debt-to-EBITDA | 2.70 |
Debt-to-EBITDA ranked
higher than
53.33%
of
495
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
SNY:
2.7
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: 0.7, Med: 1.49, Max: 2.7
Current: 2.7
|
| Interest Coverage | 14.38 |
Interest Coverage ranked
lower than
64.35%
of
648
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
SNY:
14.38
Ranked among companies with meaningful Interest Coverage only.
|
Interest Coverage range over the past 10 years
Min: 8.15, Med: 12.02, Max: 22.98
Current: 14.38
|
| Piotroski F-Score | 6 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 1.63 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.50 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 11.94%
WACC 2.39%
| ||
Profitability & Growth : 7/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 17.53 |
Operating Margin ranked
higher than
80.77%
of
801
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
SNY:
17.53
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: 17.53, Med: 21.38, Max: 24.94
Current: 17.53
|
| Net Margin % | 12.07 |
Net Margin ranked
higher than
65.59%
of
802
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
SNY:
12.07
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: 11.88, Med: 13.66, Max: 23.24
Current: 12.07
|
| ROE % | 11.05 |
ROE ranked
higher than
50.60%
of
832
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
SNY:
11.05
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: 6.5, Med: 8.38, Max: 14.56
Current: 11.05
|
| ROA % | 6.12 |
ROA ranked
higher than
51.66%
of
871
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
SNY:
6.12
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: 3.78, Med: 4.71, Max: 8.23
Current: 6.12
|
| ROC (Joel Greenblatt) % | 71.62 |
ROC (Joel Greenblatt) ranked
higher than
76.84%
of
855
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
SNY:
71.62
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: 35.24, Med: 44.95, Max: 71.62
Current: 71.62
|
| 3-Year Total Revenue Growth Rate | 0.80 |
3-Year Revenue Growth Rate ranked
higher than
51.67%
of
689
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 291.9, Med: 5.8, Min: -100
SNY:
2.5
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: -3.5, Med: 6, Max: 27.4
Current: 2.5
|
| 3-Year Total EBITDA Growth Rate | -3.30 |
3-Year EBITDA Growth Rate ranked
lower than
61.51%
of
704
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
SNY:
-1.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: -6.3, Med: 2, Max: 35.5
Current: -1.6
|
| 3-Year EPS w/o NRI Growth Rate | 1.00 |
3-Year EPS w/o NRI Growth Rate ranked
lower than
66.21%
of
663
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
SNY:
1
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
|
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -13.4, Med: 1, Max: 41.7
Current: 1
|
» SNY's 30-Y Financials
Financials (Next Earnings Date: 2019-10-31)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:SNY
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Drug Manufacturers » Drug Manufacturers - Major NAICS : 325412 SIC : 2834 |
| Compare | NAS:AMGN LSE:AZN LSE:GSK NYSE:LLY NYSE:ABBV NAS:GILD NYSE:BMY NAS:CELG XTER:BAYA NAS:BIIB TSE:4519 TSE:4568 TSE:4503 TSE:4578 XMAD:GRF.P XSWX:NOVN HKSE:01093 TSE:4151 SHSE:600436 TSE:4528 |
| Traded in other countries | SANO.Austria SAN.France SNW.Germany SANF.Italy SNYN.Mexico SAN.Switzerland 0O59.UK |
| Address | 54, Rue La Boétie, Paris, FRA, 75008 |
| Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just over 10% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent most of the remainder of sales. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 22.60 |
PE Ratio ranked
lower than
55.30%
of
557
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
SNY:
22.6
Ranked among companies with meaningful PE Ratio only.
|
PE Ratio range over the past 10 years
Min: 9.55, Med: 19.89, Max: 32.04
Current: 22.6
|
| Forward PE Ratio | 13.14 |
Forward P/E ranked
higher than
81.98%
of
111
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
SNY:
13.14
Ranked among companies with meaningful Forward P/E only.
| N/A |
| PE Ratio without NRI | 22.54 |
PE without NRI ranked
lower than
58.09%
of
556
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
SNY:
22.54
Ranked among companies with meaningful PE without NRI only.
|
PE without NRI range over the past 10 years
Min: 11.06, Med: 21.41, Max: 32.67
Current: 22.54
|
| Price-to-Owner-Earnings | 20.18 |
Price-to-Owner-Earnings ranked
higher than
90.43%
of
324
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
SNY:
20.18
Ranked among companies with meaningful Price-to-Owner-Earnings only.
|
Price-to-Owner-Earnings range over the past 10 years
Min: 7.31, Med: 13.26, Max: 21.33
Current: 20.18
|
| PB Ratio | 1.67 |
PB Ratio ranked
higher than
71.31%
of
819
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
SNY:
1.67
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 1.16, Med: 1.61, Max: 2.33
Current: 1.67
|
| PS Ratio | 2.73 |
PS Ratio ranked
higher than
55.10%
of
775
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
SNY:
2.73
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 1.8, Med: 2.64, Max: 4.12
Current: 2.73
|
| Price-to-Free-Cash-Flow | 27.25 |
Price-to-Free-Cash-Flow ranked
higher than
74.50%
of
298
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
SNY:
27.25
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
|
Price-to-Free-Cash-Flow range over the past 10 years
Min: 7.49, Med: 15.47, Max: 27.97
Current: 27.25
|
| Price-to-Operating-Cash-Flow | 17.52 |
Price-to-Operating-Cash-Flow ranked
higher than
77.30%
of
392
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
SNY:
17.52
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
|
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 6.08, Med: 11.49, Max: 18
Current: 17.52
|
| EV-to-EBIT | 23.61 |
EV-to-EBIT ranked
higher than
53.67%
of
572
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
SNY:
23.61
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: 9.6, Med: 16.7, Max: 24.6
Current: 23.61
|
| EV-to-EBITDA | 12.54 |
EV-to-EBITDA ranked
higher than
76.72%
of
597
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
SNY:
12.54
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: 5.1, Med: 9.8, Max: 14.6
Current: 12.54
|
| EV-to-Revenue | 3.21 |
EV-to-Revenue ranked
higher than
61.89%
of
795
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
SNY:
3.21
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 1.9, Med: 2.9, Max: 4.4
Current: 3.21
|
| Shiller PE Ratio | 18.39 |
Shiller PE Ratio ranked
higher than
82.54%
of
252
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 1460.4, Med: 32.75, Min: 0.08
SNY:
18.39
Ranked among companies with meaningful Shiller PE Ratio only.
|
Shiller PE Ratio range over the past 10 years
Min: 14.6, Med: 19.22, Max: 27.44
Current: 18.39
|
| Current Ratio | 1.42 |
Current Ratio ranked
lower than
100.00%
of
855
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
SNY:
1.42
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 0.79, Med: 1.72, Max: 2.71
Current: 1.42
|
| Quick Ratio | 0.99 |
Quick Ratio ranked
lower than
100.00%
of
855
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
SNY:
0.99
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 0.59, Med: 1.27, Max: 2.41
Current: 0.99
|
| Days Inventory | 152.10 |
Days Inventory ranked
lower than
95.50%
of
755
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
SNY:
152.1
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 152.1, Med: 217.06, Max: 230.38
Current: 152.1
|
| Days Sales Outstanding | 74.27 |
Days Sales Outstanding ranked
higher than
54.03%
of
770
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
SNY:
74.27
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 69.78, Med: 76.56, Max: 83.73
Current: 74.27
|
| Days Payable | 160.91 |
Days Payable ranked
higher than
77.97%
of
758
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
SNY:
160.91
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 104.92, Med: 125.26, Max: 160.91
Current: 160.91
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| Dividend Yield % | 4.02 |
Trailing Dividend Yield ranked
higher than
91.89%
of
752
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 25.84, Med: 1.54, Min: 0.04
SNY:
4.02
Ranked among companies with meaningful Trailing Dividend Yield only.
|
Trailing Dividend Yield range over the past 10 years
Min: 2.83, Med: 3.96, Max: 5.24
Current: 4.02
|
| Dividend Payout Ratio | 1.09 |
Dividend Payout Ratio ranked
lower than
92.45%
of
477
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 68, Med: 0.3, Min: 0.02
SNY:
1.09
Ranked among companies with meaningful Dividend Payout Ratio only.
|
Dividend Payout Ratio range over the past 10 years
Min: 0.55, Med: 0.86, Max: 1.09
Current: 1.09
|
| 3-Year Dividend Growth Rate (Per Share) | 2.10 |
3-Year Dividend Growth Rate ranked
lower than
67.22%
of
299
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 114, Med: 7.4, Min: -100
SNY:
2.1
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
|
3-Year Dividend Growth Rate range over the past 10 years
Min: -15.6, Med: 6.5, Max: 37.9
Current: 2.1
|
| Forward Dividend Yield % | 4.08 |
Forward Dividend Yield ranked
higher than
91.93%
of
719
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 25.84, Med: 1.66, Min: 0.04
SNY:
4.08
Ranked among companies with meaningful Forward Dividend Yield only.
| N/A |
| Yield-on-Cost (5-Year) % | 4.47 |
Yield-on-Cost (5y) ranked
higher than
88.86%
of
745
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 42.46, Med: 2.12, Min: 0.03
SNY:
4.47
Ranked among companies with meaningful Yield-on-Cost (5y) only.
|
Yield-on-Cost (5y) range over the past 10 years
Min: 3.11, Med: 4.35, Max: 5.76
Current: 4.47
|
| 3-Year Share Buyback Rate | 1.30 |
3-Year Share Buyback Rate ranked
higher than
95.80%
of
571
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 100, Med: -5.3, Min: -815
SNY:
1.3
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -24.5, Med: 0.5, Max: 2.2
Current: 1.3
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Projected-FCF | 0.97 |
Price-to-Intrinsic-Value-Projected-FCF ranked
lower than
100.00%
of
374
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 209, Med: 2.11, Min: 0.05
SNY:
0.97
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
|
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.58, Med: 0.93, Max: 1.45
Current: 0.97
|
| Price-to-Median-PS-Value | 1.03 |
Price-to-Median-PS-Value ranked
lower than
100.00%
of
743
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
SNY:
1.03
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.7, Med: 1.13, Max: 3.59
Current: 1.03
|
| Earnings Yield (Joel Greenblatt) % | 4.22 |
Earnings Yield (Greenblatt) ranked
higher than
69.43%
of
867
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
SNY:
4.22
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: 4.1, Med: 6, Max: 10.5
Current: 4.22
|
| Forward Rate of Return (Yacktman) % | 5.43 |
Forward Rate of Return ranked
lower than
60.33%
of
421
companies
in the
Drug Manufacturers - Major
industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
SNY:
5.43
Ranked among companies with meaningful Forward Rate of Return only.
|
Forward Rate of Return range over the past 10 years
Min: 1, Med: 6.1, Max: 19.2
Current: 5.43
|
More Statistics
| Revenue (TTM) (Mil) $ | 41,095.81 |
| EPS (TTM) $ | 1.97 |
| Beta | 0.4 |
| Volatility % | 14.58 |
| 52-Week Range $ | 38.97 - 45.62 |
| Shares Outstanding (Mil) | 2,496.07 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 6 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | N |
| CFROA > ROA | Y |
| Lower Leverage yoy | N |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | Y |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | Y |
» More articles for SNY
Headlines
Log In